Outset Medical Inc (OM)

$2.16

+0.08

(+3.85%)▲

Market is closed - opens 7 PM, 18 Apr 2024

Insights on Outset Medical Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 30.36M → 30.50M (in $), with an average increase of 0.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -46.18M → -38.6M (in $), with an average increase of 19.6% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 31.7% return, outperforming this stock by 119.3%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 66.1% return, outperforming this stock by 162.1%

Performance

  • $2.10
    $2.30
    $2.16
    downward going graph

    2.78%

    Downside

    Day's Volatility :8.7%

    Upside

    6.09%

    downward going graph
  • $1.92
    $24.13
    $2.16
    downward going graph

    11.11%

    Downside

    52 Weeks Volatility :92.04%

    Upside

    91.05%

    downward going graph

Returns

PeriodOutset Medical IncSector (Health Care)Index (Russel 2000)
3 Months
-38.11%
-0.7%
0.0%
6 Months
-48.57%
6.6%
0.0%
1 Year
-87.64%
3.7%
-1.5%
3 Years
-95.99%
14.0%
-21.8%

Highlights

Market Capitalization
107.5M
Book Value
$2.44
Earnings Per Share (EPS)
-3.48
Wall Street Target Price
5.79
Profit Margin
-132.54%
Operating Margin TTM
-122.44%
Return On Assets TTM
-29.73%
Return On Equity TTM
-93.69%
Revenue TTM
130.4M
Revenue Per Share TTM
2.63
Quarterly Revenue Growth YOY
-4.7%
Gross Profit TTM
17.8M
EBITDA
-164.0M
Diluted Eps TTM
-3.48
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.07
EPS Estimate Next Year
-1.8
EPS Estimate Current Quarter
-0.61
EPS Estimate Next Quarter
-0.52

Analyst Recommendation

Buy
    66%Buy
    26%Hold
    6%Sell
Based on 15 Wall street analysts offering stock ratings for Outset Medical Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
11
11
Hold
4
4
3
Sell
1
00
00

Analyst Forecast

What analysts predicted

Upside of 168.06%

Current $2.16
Target $5.79

Company Financials

FY18Y/Y Change
Revenue
2.0M
-
Net Income
-49.8M
-
Net Profit Margin
-2.5K%
-
FY19Y/Y Change
Revenue
15.1M
↑ 651.27%
Net Income
-68.3M
↑ 37.2%
Net Profit Margin
-452.97%
↑ 2027.35%
FY20Y/Y Change
Revenue
49.9M
↑ 231.18%
Net Income
-120.7M
↑ 76.72%
Net Profit Margin
-241.71%
↑ 211.26%
FY21Y/Y Change
Revenue
102.6M
↑ 105.47%
Net Income
-131.9M
↑ 9.31%
Net Profit Margin
-128.59%
↑ 113.12%
FY22Y/Y Change
Revenue
115.4M
↑ 12.45%
Net Income
-163.0M
↑ 23.51%
Net Profit Margin
-141.24%
↓ 12.65%
FY23Y/Y Change
Revenue
130.4M
↑ 13.0%
Net Income
-172.8M
↑ 6.04%
Net Profit Margin
-132.54%
↑ 8.7%
Q3 FY22Q/Q Change
Revenue
27.8M
↑ 10.79%
Net Income
-40.8M
↓ 6.98%
Net Profit Margin
-146.9%
↑ 28.06%
Q4 FY22Q/Q Change
Revenue
32.0M
↑ 15.29%
Net Income
-41.4M
↑ 1.63%
Net Profit Margin
-129.48%
↑ 17.42%
Q1 FY23Q/Q Change
Revenue
33.5M
↑ 4.56%
Net Income
-44.0M
↑ 6.1%
Net Profit Margin
-131.39%
↓ 1.91%
Q2 FY23Q/Q Change
Revenue
36.0M
↑ 7.69%
Net Income
-44.0M
↑ 0.17%
Net Profit Margin
-122.21%
↑ 9.18%
Q3 FY23Q/Q Change
Revenue
30.4M
↓ 15.75%
Net Income
-46.2M
↑ 4.84%
Net Profit Margin
-152.1%
↓ 29.89%
Q4 FY23Q/Q Change
Revenue
30.5M
↑ 0.48%
Net Income
-38.6M
↓ 16.41%
Net Profit Margin
-126.53%
↑ 25.57%
FY18Y/Y Change
Total Assets
151.1M
-
Total Liabilities
439.1M
-
FY19Y/Y Change
Total Assets
88.4M
↓ 41.53%
Total Liabilities
460.6M
↑ 4.89%
FY20Y/Y Change
Total Assets
403.8M
↑ 357.0%
Total Liabilities
75.2M
↓ 83.67%
FY21Y/Y Change
Total Assets
463.5M
↑ 14.77%
Total Liabilities
89.4M
↑ 18.83%
FY22Y/Y Change
Total Assets
400.1M
↓ 13.67%
Total Liabilities
154.1M
↑ 72.43%
FY23Y/Y Change
Total Assets
313.8M
↓ 21.57%
Total Liabilities
190.9M
↑ 23.87%
Q3 FY22Q/Q Change
Total Assets
365.7M
↓ 8.85%
Total Liabilities
86.6M
↓ 5.31%
Q4 FY22Q/Q Change
Total Assets
400.1M
↑ 9.4%
Total Liabilities
154.1M
↑ 77.93%
Q1 FY23Q/Q Change
Total Assets
362.7M
↓ 9.36%
Total Liabilities
146.4M
↓ 5.03%
Q2 FY23Q/Q Change
Total Assets
334.4M
↓ 7.78%
Total Liabilities
151.3M
↑ 3.39%
Q3 FY23Q/Q Change
Total Assets
307.6M
↓ 8.04%
Total Liabilities
155.5M
↑ 2.74%
Q4 FY23Q/Q Change
Total Assets
313.8M
↑ 2.03%
Total Liabilities
190.9M
↑ 22.78%
FY18Y/Y Change
Operating Cash Flow
-46.4M
-
Investing Cash Flow
-68.8M
-
Financing Cash Flow
134.9M
-
FY19Y/Y Change
Operating Cash Flow
-70.3M
↑ 51.35%
Investing Cash Flow
74.3M
↓ 208.03%
Financing Cash Flow
249.0K
↓ 99.82%
FY20Y/Y Change
Operating Cash Flow
-99.0M
↑ 40.86%
Investing Cash Flow
3.9M
↓ 94.69%
Financing Cash Flow
385.7M
↑ 154792.37%
FY21Y/Y Change
Operating Cash Flow
-130.3M
↑ 31.56%
Investing Cash Flow
-142.5M
↓ 3710.51%
Financing Cash Flow
160.1M
↓ 58.48%
FY22Y/Y Change
Operating Cash Flow
-145.7M
↑ 11.87%
Investing Cash Flow
-66.3M
↓ 53.48%
Financing Cash Flow
72.9M
↓ 54.48%
Q3 FY22Q/Q Change
Operating Cash Flow
-34.3M
↓ 11.05%
Investing Cash Flow
20.2M
↓ 1631.84%
Financing Cash Flow
2.5M
↑ 143.09%
Q4 FY22Q/Q Change
Operating Cash Flow
-34.5M
↑ 0.57%
Investing Cash Flow
-51.7M
↓ 356.7%
Financing Cash Flow
65.6M
↑ 2489.81%
Q1 FY23Q/Q Change
Operating Cash Flow
-44.8M
↑ 29.7%
Investing Cash Flow
2.6M
↓ 105.11%
Financing Cash Flow
5.3M
↓ 91.96%

Technicals Summary

Sell

Neutral

Buy

Outset Medical Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Outset Medical Inc
Outset Medical Inc
8.0%
-48.57%
-87.64%
-95.99%
-96.44%
Stryker Corporation
Stryker Corporation
-5.1%
24.37%
15.51%
30.88%
86.41%
Boston Scientific Corp.
Boston Scientific Corp.
1.07%
34.02%
31.68%
66.24%
93.56%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-6.04%
25.15%
3.43%
-1.49%
47.65%
Abbott Laboratories
Abbott Laboratories
-5.82%
10.82%
1.68%
-14.96%
43.26%
Medtronic Plc
Medtronic Plc
-5.47%
8.78%
-3.15%
-37.3%
-6.1%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Outset Medical Inc
Outset Medical Inc
NA
NA
NA
-2.07
-0.94
-0.3
NA
2.44
Stryker Corporation
Stryker Corporation
40.98
40.98
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
63.66
63.66
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
39.15
39.15
5.19
2.76
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
33.4
33.4
5.99
4.59
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.16
25.16
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Outset Medical Inc
Outset Medical Inc
Buy
$107.5M
-96.44%
NA
-132.54%
Stryker Corporation
Stryker Corporation
Buy
$128.5B
86.41%
40.98
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$100.1B
93.56%
63.66
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$54.2B
47.65%
39.15
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$189.5B
43.26%
33.4
14.27%
Medtronic Plc
Medtronic Plc
Buy
$105.2B
-6.1%
25.16
13.0%

Institutional Holdings

  • FMR Inc

    13.99%

  • JPMorgan Chase & Co

    9.82%

  • Vanguard Group Inc

    7.80%

  • Morgan Stanley - Brokerage Accounts

    7.66%

  • BlackRock Inc

    7.51%

  • T. Rowe Price Investment Management,Inc.

    6.27%

Corporate Announcements

  • Outset Medical Inc Earnings

    Outset Medical Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

outset is a pioneering medical technology company that always puts the patient before the machine. our human-centered model is designed to dramatically improve not only the care experience – for patients, families, providers and physicians alike – but also cost-efficiencies for providers. and to achieve this goal, we brought together the most dedicated, creative minds from dialysis with the most dedicated, creative minds from other healthcare fields, in the belief that cross-fertilization – along with hard work – is the surest path to invention. because we believe a dialysis machine should be as easy to use as an everyday consumer product, tablo was designed with simplicity in mind. one example is tablo’s touchscreen display, which offers step-by-step pictures and conversational instructions that make it hard to mess up no matter how new a patient, or caregiver, may be to dialysis. and with simplicity comes speed. we’ve set out to give people their time back. tablo dramatically reduces

Organization
Outset Medical Inc
Employees
480
CEO
Ms. Leslie L. Trigg
Industry
Health Technology

Discover More

FAQs